Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hydralazine as demethylating agent in breast cancer

Next Previous
Trial Profile

Hydralazine as demethylating agent in breast cancer

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antineoplastics; Hydralazine
  • Indications Breast cancer
  • Focus Adverse reactions

Most Recent Events

  • 04 Mar 2015 Biomarkers information updated
  • 04 Dec 2008 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
  • 02 Jun 2008 The expected completion date for this trial is now 1 Dec 2009 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top